Oct 23, 2018
Amneal Announces Approval and Launch of Clobazam Tablets and Clobazam Oral Suspension
Oct 19, 2018
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
Sep 24, 2018
Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 21, 2018
Amneal to Report Third Quarter 2018 Results on November 7, 2018
Sep 12, 2018
Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP
Sep 11, 2018
Global Primary Sclerosing Cholangitis Treatment Market 2018-2022: Key Vendors are Allergan, Glenmark, Impax Laboratories, Mylan & Teva Pharmaceuticals
Aug 31, 2018
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
Aug 31, 2018
Amneal to Present at Upcoming Investor Conferences
Aug 20, 2018
Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine
Jul 23, 2018
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
Jun 29, 2018
Amneal to Report Second Quarter 2018 Results on August 9, 2018
Jun 29, 2018
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
Jun 26, 2018
Autoinjectors Market, 2030
Jun 20, 2018
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary®
Jun 06, 2018
Amneal to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
May 30, 2018
Amneal Announces FDA Approval of Cyclophosphamide for Injection USP, Generic to Cytoxan®
May 23, 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
May 14, 2018
Amneal to Present at the UBS Global Healthcare Conference
May 02, 2018
Amneal Launches Generic for Sabril®: Vigabatrin for Oral Solution, USP
Mar 01, 2018
Amneal Launches Generic for Tamiflu® Oral Suspension